Corneal Collagen Cross-linking for Progressive Keratoconus
NCT ID: NCT00647699
Last Updated: 2021-04-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
147 participants
INTERVENTIONAL
2007-12-31
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery
NCT01459679
Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia
NCT01726283
Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
NCT01097447
Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
NCT01152541
Adapted Fluence Settings for Corneal Collagen Cross-linking in Mild to Moderate Progressive Keratoconus
NCT02507362
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Corneal Collagen Cross-linking (CXL) Treatment Group
riboflavin ophthalmic solution and UVA irradiation
riboflavin ophthalmic solution
riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
UVA Irradiation
UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Control Group
riboflavin ophthalmic solution without UVA irradiation.
riboflavin ophthalmic solution
riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
riboflavin ophthalmic solution
riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
UVA Irradiation
UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented progression over previous 24 months
* Decreased BSCVA
* Must complete all study visits
Exclusion Criteria
* History of delayed wound healing
14 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Glaukos Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Hersh, MD
Role: PRINCIPAL_INVESTIGATOR
Cornea and Laser Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shiley Eye Center
La Jolla, California, United States
Gordon -Weiss Vision Institute
San Diego, California, United States
Center for Excellence in Eye Care
Miami, Florida, United States
Price Vision Group
Indianapolis, Indiana, United States
Durrie Vision
Kansas City, Kansas, United States
Wilmer Eye Institute at Johns Hopkins University
Baltimore, Maryland, United States
Minnesota Eye Consultants
Minneapolis, Minnesota, United States
Cornea & Laser Eye Institute; Hersh Vision Group
Teaneck, New Jersey, United States
Edward Harkness Eye Institute at Columbia University Medical Center
New York, New York, United States
Ophthalmic Consultants of Long Island
Rockville Centre, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Greenstein SA, Fry KL, Hersh PS. Effect of topographic cone location on outcomes of corneal collagen cross-linking for keratoconus and corneal ectasia. J Refract Surg. 2012 Jun;28(6):397-405. doi: 10.3928/1081597X-20120518-02.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UVX-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.